HSBC/CALL/AMGEN/300/0.1/16.01.26 | Market Closed - BOERSE MUENCHEN 20:35:16 15/07/2024 BST | ||
| 5.96 EUR | -1.97% |
|
| Current month | +24.08% | ||
| 1 month | +45.80% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 15/07/24 | 5.96 | -1.97% |
| 12/07/24 | 6.08 | +7.80% |
| 11/07/24 | 5.64 | +6.42% |
| 10/07/24 | 5.3 | +6.85% |
| 09/07/24 | 4.96 | +3.55% |
Real-time BOERSE MUENCHEN
Last update July 15, 2024 at 08:35 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | HSBC |
| WKN | HS2FUR |
| ISIN | DE000HS2FUR7 |
| Date issued | 28/09/2023 |
| Strike | 300 $ |
| Maturity | 16/01/2026 (550 Days) |
| Parity | 10 : 1 |
| Emission price | 3.5 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.2 € |
|---|---|
| Lowest since issue | 2.52 € |
| Spread | 0.02 € |
| Spread % | 0.34% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
330.2
USD
Average target price
317.4
USD
Spread / Average Target
-3.86%
- Stock Market
- Warrants
- Warrant
